Search

Your search keyword '"Craxi A."' showing total 1,617 results
Start Over Author "Craxi A."
1,617 results on '"Craxi A."'

101. SIRT5 rs12216101 T > G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD

Author

Salomone, Federico, primary, Pipitone, Rosaria Maria, additional, Malvestiti, Francesco, additional, Dongiovanni, Paola, additional, Longo, Miriam, additional, Amorini, Angela Maria, additional, Distefano, Alfio, additional, Li Volti, Giovanni, additional, Lazzarino, Giuseppe, additional, Ciociola, Ester, additional, Pennisi, Grazia, additional, Porcasi, Rossana, additional, Cabibi, Daniela, additional, Craxi, Antonio, additional, Fracanzani, Anna Ludovica, additional, Valenti, Luca, additional, Petta, Salvatore, additional, and Grimaudo, Stefania, additional

Published
2022
Full Text
View/download PDF

102. Diagnostic performance of AGILE 3+ score for identification of advanced fibrosis and prediction of liver-related events in patients with non-alcoholic fatty liver disease

Author

Pennisi, Grazia, primary, Celsa, Ciro, additional, Enea, Marco, additional, Pandolfo, Alessandra, additional, Antonucci, Michela, additional, Ciccioli, Carlo, additional, Infantino, Giuseppe, additional, La Mantia, Claudia, additional, Parisi, Stefanie, additional, Tulone, Adele, additional, Di Marco, Vito, additional, Craxi, Antonio, additional, Camma, Calogero, additional, and Petta, Salvatore, additional

Published
2022
Full Text
View/download PDF

103. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

Author

A Kondili, L, Gamkrelidze, I, Blach, S, Marcellusi, A, Galli, M, Petta, S, Puoti, M, Vella, S, Razavi, H, Craxi, A, S Mennini, F, collaborating group, P, Loreta A Kondili, Ivane Gamkrelidze, Sarah Blach, Andrea Marcellusi, Massimo Galli, Salvatore Petta, Massimo Puoti, Stefano Vella, Homie Razavi, Antonio Craxi, Francesco S Mennini, PITER collaborating group, A Kondili, L, Gamkrelidze, I, Blach, S, Marcellusi, A, Galli, M, Petta, S, Puoti, M, Vella, S, Razavi, H, Craxi, A, S Mennini, F, collaborating group, P, Loreta A Kondili, Ivane Gamkrelidze, Sarah Blach, Andrea Marcellusi, Massimo Galli, Salvatore Petta, Massimo Puoti, Stefano Vella, Homie Razavi, Antonio Craxi, Francesco S Mennini, and PITER collaborating group

Abstract

Background and Aims: Cost-effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost-effective in Italy. Methods: A model was developed to quantify screening and healthcare costs associated with HCV. The model-estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost-effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results: A graduated birth cohort screening strategy (graduated screening 1: 1968-1987 birth cohorts, then expanding to 1948-1967 cohorts) was the least costly. This strategy would gain approximately 144 000 quality-adjusted life years (QALYs) by 2031 and result in an 89.3% reduction in HCV cases, compared to an 89.6%, 89.0%, 89.7% and 88.7% reduction for inversed graduated screening, 1948-77 birth cohort, 1958-77 birth cohort and universal screening, respectively. Graduated screening 1 yielded the lowest incremental cost-effectiveness ratio (ICER) of €3552 per QALY gained. Conclusions: In Italy, a graduated screening scenario is the most cost-effective strategy. Other countries could consider a similar birth cohort approach when developing HCV screening strategies.

Published
2020

104. Primary Biliary Cholangitis management: controversies, perspectives, and daily practice implications from an expert panel

Author

Alvaro, D, Carpino, G, Craxi, A, Floreani, A, Moschetta, A, Invernizzi, P, Alvaro, Domenico, Carpino, Guido, Craxi, Antonio, Floreani, Annarosa, Moschetta, Antonio, Invernizzi, Pietro, Alvaro, D, Carpino, G, Craxi, A, Floreani, A, Moschetta, A, Invernizzi, P, Alvaro, Domenico, Carpino, Guido, Craxi, Antonio, Floreani, Annarosa, Moschetta, Antonio, and Invernizzi, Pietro

Abstract

Primary biliary cholangitis (PBC) is a rare progressive immune-mediated liver disease that, if not adequately treated, may culminate in end-stage disease and need for transplantation. According to current guidelines, PBC is diagnosed in the presence of anti-mitochondrial antibodies (AMA)- or specific anti-nuclear antibodies, and of a cholestatic biochemical profile, while biopsy is recommended only in selected cases. All patients receive ursodeoxycholic acid (UDCA) in first line; the only registered second line-therapy is obeticholic acid for UDCA-inadequate responders. Despite the recent advances in understanding PBC pathogenesis and developing new treatments, many grey areas remain. Six Italian experts selected the following topics as the most urgent to address in PBC management: diagnosis and natural history of PBC: as a portion of the subjects with isolated AMA, normal alkaline phosphatase levels and no symptoms of liver disease could have PBC by histology, defining how to manage and follow this population is crucial; role of liver biopsy: recent evidence suggests that biopsy may provide relevant information for risk stratification and prediction of UDCA response, possibly facilitating personalized approaches; risk stratification: the tools for risk stratification are well established, but some issues (e.g. bile acid dosage in routine practice) remain controversial; therapy: those in more advanced stages of development are nuclear receptor modulators and fibrates, but more data are needed to plan personalized strategies. In this manuscript, for each topic, current evidence, controversies, and future perspectives are summarized with the possible implications for clinical practice.

Published
2020

106. OC.08.1 PROGRAMMED CELL DEATH 1 GENETIC VARIANT AND LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE

Author

R.M. Pipitone, F. Malvestiti, G. Pennisi, O. Jamialahmadi, P. Dongiovanni, G. Bertolazzi, J. Pihlajamaki, H. Yki-Jarvinen, U. Vespasiani-Gentilucci, F. Tavaglione, S. Maurotti, C. Bianco, G. Di Maria, M. Enea, A. Fracanzani, V. Karja, G. Lupo, V. Mannisto, M. Meroni, R. Piciotti, S. Qadri, R. Zito, A. Craxi, V. Di Marco, C. Camma, C. Tripodo, L. Valenti, S. Romeo, S. Petta, and S. Grimaudo

Subjects
Hepatology, Gastroenterology
Published
2023

107. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

Author

Kondili L. A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F. S., on behalf of PITER collaborating group, Federico A., Dallio M., Loguercio C., A Kondili, L, Gamkrelidze, I, Blach, S, Marcellusi, A, Galli, M, Petta, S, Puoti, M, Vella, S, Razavi, H, Craxi, A, S Mennini, F, collaborating group, P, Kondili L.A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F.S., Kondili, L. A., Gamkrelidze, I., Blach, S., Marcellusi, A., Galli, M., Petta, S., Puoti, M., Vella, S., Razavi, H., Craxi, A., Mennini, F. S., on behalf of PITER collaborating, Group, Federico, A., Dallio, M., and Loguercio, C.

Subjects
medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Hepatitis C virus, Settore SECS-P/06, cost-effectivene, Hepacivirus, medicine.disease_cause, Antiviral Agents, World health, NO, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Mass Screening, cost-effectiveness, Antibody screens, Hepatology, Under-five, business.industry, screening, Health services research, health, cost‐effectiveness, Hepatitis C, Chronic, Hepatitis C, Italy, 030220 oncology & carcinogenesis, Settore MED/42, HCV, Original Article, epidemiology, 030211 gastroenterology & hepatology, Liver Disease and Public Health, Quality-Adjusted Life Years, Birth cohort, business, WHO targets, cost-effectiveness, HCV, screening, WHO targets, Demography
Abstract

Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The model‐estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost‐effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results A graduated birth cohort screening strategy (graduated screening 1: 1968‐1987 birth cohorts, then expanding to 1948‐1967 cohorts) was the least costly. This strategy would gain approximately 144 000 quality‐adjusted life years (QALYs) by 2031 and result in an 89.3% reduction in HCV cases, compared to an 89.6%, 89.0%, 89.7% and 88.7% reduction for inversed graduated screening, 1948‐77 birth cohort, 1958‐77 birth cohort and universal screening, respectively. Graduated screening 1 yielded the lowest incremental cost‐effectiveness ratio (ICER) of €3552 per QALY gained. Conclusions In Italy, a graduated screening scenario is the most cost‐effective strategy. Other countries could consider a similar birth cohort approach when developing HCV screening strategies., See Editorial on Page 1538

Published
2020

108. A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease

Author

Fonds de Recherche du Québec, Pennisi, Grazia, Pipitone, Rosaria Maria, Cabibi, Daniela, Enea, Marco, Romero-Gómez, Manuel, Viganò, Mauro, Bugianesi, Elisabetta, Wong, Vincent W., Fracanzani, Anna Ludovica, Sebastiani, Giada, Berzigotti, Annalisa, Di Salvo, Francesca, Giannone, Antonino Giulio, La Mantia, Claudia, Lupo, Giulia, Porcasi, Rossana, Vernuccio, Federica, Zito, Rossella, Di Marco, Vito, Cammà, Calogero, Craxi, Antonio, Ledinghen, Victor de, Grimaudo, Stefania, Petta, Salvatore, Fonds de Recherche du Québec, Pennisi, Grazia, Pipitone, Rosaria Maria, Cabibi, Daniela, Enea, Marco, Romero-Gómez, Manuel, Viganò, Mauro, Bugianesi, Elisabetta, Wong, Vincent W., Fracanzani, Anna Ludovica, Sebastiani, Giada, Berzigotti, Annalisa, Di Salvo, Francesca, Giannone, Antonino Giulio, La Mantia, Claudia, Lupo, Giulia, Porcasi, Rossana, Vernuccio, Federica, Zito, Rossella, Di Marco, Vito, Cammà, Calogero, Craxi, Antonio, Ledinghen, Victor de, Grimaudo, Stefania, and Petta, Salvatore

Abstract

NAFLD patients usually have an increase in AST/ALT levels, but cholestasis can also be observed. We aimed to assess in subjects with NAFLD the impact of the (cholestatic) C pattern on the likelihood of developing major liver-related outcomes (MALO).

Published
2022

109. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020:a modelling study

Author

Blach, Sarah, Terrault, Norah A., Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J., Abbas, Zaigham, Abdallah, Ayat R., Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S., Alalwan, Abduljaleel M., Alanko Blomé, Marianne, Al-Busafi, Said A., Aleman, Soo, Alghamdi, Abdullah S., Al-Hamoudi, Waleed K., Aljumah, Abdulrahman A., Al-Naamani, Khalid, Al Serkal, Yousif M., Altraif, Ibrahim H., Anand, Anil C., Anderson, Motswedi, Andersson, Monique I., Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R., Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J., Bizri, Abdul Rahman N., Brandão-Mello, Carlos E., Brigida, Krestina, Brown, Kimberly A., Brown,, Robert S., Bruggmann, Philip, Brunetto, Maurizia R., Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Weis, Nina, Blach, Sarah, Terrault, Norah A., Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J., Abbas, Zaigham, Abdallah, Ayat R., Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S., Alalwan, Abduljaleel M., Alanko Blomé, Marianne, Al-Busafi, Said A., Aleman, Soo, Alghamdi, Abdullah S., Al-Hamoudi, Waleed K., Aljumah, Abdulrahman A., Al-Naamani, Khalid, Al Serkal, Yousif M., Altraif, Ibrahim H., Anand, Anil C., Anderson, Motswedi, Andersson, Monique I., Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R., Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J., Bizri, Abdul Rahman N., Brandão-Mello, Carlos E., Brigida, Krestina, Brown, Kimberly A., Brown,, Robert S., Bruggmann, Philip, Brunetto, Maurizia R., Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, and Weis, Nina

Abstract

Background: Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends. Methods: This analysis includes a literature review, Delphi process, and mathematical modelling to estimate HCV prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥0 years from birth) for the period between Jan 1, 2015, and Dec 31, 2030. Epidemiological data were collected from published sources and grey literature (including government reports and personal communications) and were validated among country and territory experts. A Markov model was used to forecast disease burden and cascade of care from 1950 to 2050 for countries and territories with data. Model outcomes were extracted from 2015 to 2030 to calculate population-weighted regional averages, which were used for countries or territories without data. Regional and global estimates of HCV prevalence, cascade of care, and disease burden were calculated based on 235 countries and territories. Findings: Models were built for 110 countries or territories: 83 were approved by local experts and 27 were based on published data alone. Using data from these models, plus population-weighted regional averages for countries and territories without models (n=125), we estimated a global prevalence of viraemic HCV infection of 0·7% (95% UI 0·7–0·9), corresponding to 56·8 million (95% UI 55·2–67·8) infections, on Jan 1, 2020. This number represents a decrease of 6·8 million viraemic infections from a 2015 (beginning of year) prevalence estimate of 63·6 million (61·8–75·8) infections (0·9% [0·8–1·0] prevalence). By the end of 2020, an estimated 12·9 million (12·5–15·4) people were living with a diagnosed viraemic inf

Published
2022

112. Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial

Author

Noto, Davide, primary, Petta, Salvatore, additional, Giammanco, Antonina, additional, Spina, Rossella, additional, Cabibbi, Daniela, additional, Porcasi, Rossana, additional, Caldarella, Rosalia, additional, Ciaccio, Marcello, additional, Muratore, Roberto, additional, Cefalù, Angelo B., additional, Craxi, Antonio, additional, and Averna, Maurizio, additional

Published
2022
Full Text
View/download PDF

113. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.

Author

Serena Pelusi, Salvatore Petta, Chiara Rosso, Vittorio Borroni, Anna Ludovica Fracanzani, Paola Dongiovanni, Antonio Craxi, Elisabetta Bugianesi, Silvia Fargion, and Luca Valenti

Subjects
Medicine, Science
Abstract

BACKGROUND:The clinical determinants of fibrosis progression in nonalcoholic fatty liver disease (NAFLD) are still under definition. AIM:To assess the clinical determinants of fibrosis progression rate (FPR) in NAFLD patients with baseline and follow-up histological evaluation, with a special focus on the impact of pharmacological therapy. METHODS:In an observational cohort of 118 Italian patients from tertiary referral centers, liver histology was evaluated according to Kleiner. Independent predictors of FPR were selected by a stepwise regression approach. RESULTS:Median follow-up was 36 months (IQR 24-77). Twenty-five patients (18%) showed some amelioration, 63 (53%) had stability, 30 (25%) had progression of fibrosis. Patients with nonalcoholic steatohepatitis (NASH) had similar demographic and anthropometric features, but a higher prevalence of type 2 diabetes (T2D; p = 0.010), and use of renin-angiotensin axis system (RAS) inhibitors (p = 0.005). Fibrosis progression was dependent of the length of follow-up, and was associated with, but did not require, the presence of NASH (p

Published
2016
Full Text
View/download PDF

114. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figueroa, M.P. Hofmann, W.P. Petta, S. de Oliveira, C.P.M.S. Puri, P. Pan, C.Q. Rac, M. Ralston, J. Ramji, A. Razavi, H. Alvares-da-Silva, M.R. Roberts, S. Roden, M. Rose, T. Rouabhia, S. Rovere-Querini, P. Rowe, I.A. Sadirova, S. Salupere, R. Saparbu, T. Sayegh, R. Sebastiani, G. Seki, Y. Selmo, J. Serme, A.K. Shaw, J.E. Shenoy, T. Sheron, N. Shibolet, O. Silva, M. Skrypnyk, I. Socha, P. Soriano, J. Spearman, C.W. Sridharan, K. Suárez, J.J. Sheriff, D.S. Sung, K.-C. Swain, M. Tacke, F. Taheri, S. Tan, S.-S. Tapper, E.B. Yki-Järvinen, H. Thiele, M. Shawa, I.T. Tolmane, I. Torres, E.A. Trauner, M. Treeprasertsuk, S. Turcanu, A. Valantinas, J. Vesterhus, M. Waked, I. Wild, S.H. Willemse, J. Wong, R.J. Xanthakos, S. Young, D.Y. Yu, M.-L. Zheng, K.I. Zeybel, M. Zheng, M.-H. the NAFLD Consensus Consortium

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.

Published
2022

120. Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop

Author

Carosi, Giampiero, Rizzetto, Mario, Alberti, Alfredo, Cariti, Giuseppe, Colombo, Massimo, Craxì, Antonio, Filice, Gaetano, Levrero, Massimo, Mazzotta, Francesco, Pastore, Giuseppe, Piccinino, Felice, Prati, Daniele, Raimondo, Giovanni, Sagnelli, Evangelista, Toti, Mario, Brunetto, Maurizia, Bruno, Raffaele, Di Marco, Vito, Ferrari, Carlo, Gaeta, Giovanni B., Lampertico, Pietro, Marzano, Alfredo, Pollicino, Teresa, Puoti, Massimo, Santantonio, Teresa, and Smedile, Antonina

Published
2011
Full Text
View/download PDF

122. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Author

Raimondo, G, Locarnini, S, Pollicino, T, Levrero, M, Zoulim, F, Lok, A, Allain, J, Berg, T, Bertoletti, A, Brunetto, M, Bruno, R, Chen, D, Coppola, N, Cornberg, M, Craxi, A, Dandri, M, Di Marco, V, Ferrari, C, Gaeta, G, Glebe, D, Guidotti, L, Kramvis, A, Lampertico, P, Li, C, Liang, J, Marzano, A, Michalak, T, Pawlotsky, J, Prati, D, Puoti, M, Samuel, D, Soriano, V, Squadrito, G, Sureau, C, Trepo, C, Yuen, M, Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A. S., Allain J. -P., Berg T., Bertoletti A., Brunetto M. R., Bruno R., Chen D. -S., Coppola N., Cornberg M., Craxi A., Dandri M., Di Marco V., Ferrari C., Gaeta G. B., Glebe D., Guidotti L. G., Kramvis A., Lampertico P., Li C., Liang J., Marzano A., Michalak T. I., Pawlotsky J. -M., Prati D., Puoti M., Samuel D., Soriano V., Squadrito G., Sureau C., Trepo C., Yuen M. -F., Raimondo, G, Locarnini, S, Pollicino, T, Levrero, M, Zoulim, F, Lok, A, Allain, J, Berg, T, Bertoletti, A, Brunetto, M, Bruno, R, Chen, D, Coppola, N, Cornberg, M, Craxi, A, Dandri, M, Di Marco, V, Ferrari, C, Gaeta, G, Glebe, D, Guidotti, L, Kramvis, A, Lampertico, P, Li, C, Liang, J, Marzano, A, Michalak, T, Pawlotsky, J, Prati, D, Puoti, M, Samuel, D, Soriano, V, Squadrito, G, Sureau, C, Trepo, C, Yuen, M, Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A. S., Allain J. -P., Berg T., Bertoletti A., Brunetto M. R., Bruno R., Chen D. -S., Coppola N., Cornberg M., Craxi A., Dandri M., Di Marco V., Ferrari C., Gaeta G. B., Glebe D., Guidotti L. G., Kramvis A., Lampertico P., Li C., Liang J., Marzano A., Michalak T. I., Pawlotsky J. -M., Prati D., Puoti M., Samuel D., Soriano V., Squadrito G., Sureau C., Trepo C., and Yuen M. -F.

Abstract

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

Published
2019

123. Real life experiences in HCV management in 2018

Author

Vigano, M, Andreoni, M, Perno, C, Craxi, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, M, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, G, Gasbarrini, A, Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G, Zignego, A, Vigano M., Andreoni M., Perno C. F., Craxi A., Aghemo A., Alberti A., Andreone P., Babudieri S., Bonora S., Brunetto M. R., Bruno R., Bruno S., Calvaruso V., Caporaso N., Cartabellotta F., Ceccherini-Silberstein F., Cento V., Ciancio A., Colombatto P., Coppola N., Di Marco V., Di Perri G., Fagiuoli S., Gaeta G. B., Gasbarrini A., Lampertico P., Pellicelli A., Prestileo T., Puoti M., Raimondo G., Rizzardini G., Taliani G., Zignego A. L., Vigano, M, Andreoni, M, Perno, C, Craxi, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, M, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, G, Gasbarrini, A, Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G, Zignego, A, Vigano M., Andreoni M., Perno C. F., Craxi A., Aghemo A., Alberti A., Andreone P., Babudieri S., Bonora S., Brunetto M. R., Bruno R., Bruno S., Calvaruso V., Caporaso N., Cartabellotta F., Ceccherini-Silberstein F., Cento V., Ciancio A., Colombatto P., Coppola N., Di Marco V., Di Perri G., Fagiuoli S., Gaeta G. B., Gasbarrini A., Lampertico P., Pellicelli A., Prestileo T., Puoti M., Raimondo G., Rizzardini G., Taliani G., and Zignego A. L.

Abstract

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

Published
2019

124. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group

Author

Andreone, P, Di Marco, V, Gaeta, G, Fagiuoli, S, Vukotic, R, Craxi, A, Andreone P., Di Marco V., Gaeta G. B., Fagiuoli S., Vukotic R., Craxi A., Andreone, P, Di Marco, V, Gaeta, G, Fagiuoli, S, Vukotic, R, Craxi, A, Andreone P., Di Marco V., Gaeta G. B., Fagiuoli S., Vukotic R., and Craxi A.

Abstract

Hepatitis C virus (HCV) remains a significant public health problem and is one of the major causes of chronic liver disease worldwide. In recent years many new tools to facilitate widespread HCV screening and new therapeutic options with excellent efficacy and tolerability profiles and cost lowering policies have become available. To fully utilise these new tools, the link between local and specialist centres for the management of HCV infection must be reinforced. In order to GAIN further insight into these aspects, with a particular focus on the Italian scenario, a group of experts met to discuss relevant aspects and open issues on chronic HCV. As a summary of that meeting, the following aspects are here overviewed: (i) global situation of HCV; (ii) screening, diagnosis and indications for the treatment of HCV; (iii) the Italian situation of HCV referrals; (iv) ‘hard to reach’ patients; (v) treatment of HCV with extrahepatic manifestations; (vi) treatment of patients with advanced cirrhosis. It is the intention of the expert panel to further promote widespread screening and eradication policies that should be accompanied by greater interaction, by attempting to involve all healthcare providers in an organised process to facilitate linkage to care of patients with HCV infections.

Published
2019

125. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

Author

Calvaruso, V, Mazzarelli, C, Milazzo, L, Badia, L, Pasulo, L, Guaraldi, G, Lionetti, R, Villa, E, Borghi, V, Carrai, P, Alberti, A, Biolato, M, Piai, G, Persico, M, Santantonio, T, Felder, M, Angelico, M, Montalbano, M, Mancusi, R, Grieco, A, Angeli, E, D'Offizi, G, Fagiuoli, S, Belli, L, Verucchi, G, Puoti, M, Craxi, A, Calvaruso V., Mazzarelli C., Milazzo L., Badia L., Pasulo L., Guaraldi G., Lionetti R., Villa E., Borghi V., Carrai P., Alberti A., Biolato M., Piai G., Persico M., Santantonio T., Felder M., Angelico M., Montalbano M., Mancusi R. L., Grieco A., Angeli E., D'Offizi G., Fagiuoli S., Belli L., Verucchi G., Puoti M., Craxi A., Calvaruso, V, Mazzarelli, C, Milazzo, L, Badia, L, Pasulo, L, Guaraldi, G, Lionetti, R, Villa, E, Borghi, V, Carrai, P, Alberti, A, Biolato, M, Piai, G, Persico, M, Santantonio, T, Felder, M, Angelico, M, Montalbano, M, Mancusi, R, Grieco, A, Angeli, E, D'Offizi, G, Fagiuoli, S, Belli, L, Verucchi, G, Puoti, M, Craxi, A, Calvaruso V., Mazzarelli C., Milazzo L., Badia L., Pasulo L., Guaraldi G., Lionetti R., Villa E., Borghi V., Carrai P., Alberti A., Biolato M., Piai G., Persico M., Santantonio T., Felder M., Angelico M., Montalbano M., Mancusi R. L., Grieco A., Angeli E., D'Offizi G., Fagiuoli S., Belli L., Verucchi G., Puoti M., and Craxi A.

Abstract

We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustained virological response at week 12 post-treatment (SVR12). Liver function changes between baseline and follow up were assessed in 228 patients. 240 patients achieved SVR12 (87.3%), post transplant and HIV co-infected patients were equally distributed among SVR and no SVR (35% vs 34.3%; p = 0.56 and 24.2% vs 11.4%, p = 0.13, respectively). SVR rate was significantly higher with the combination DCV + SOF compared with DCV + SIM or ASU (93.2% vs 63.0%, p < 0.0001). Bilirubin value (OR: 0.69, CI95%: 0.54–0.87, p = 0.002) and regimen containing SOF (OR: 9.99, CI95%: 4.09–24.40; p < 0.001) were independently related with SVR. Mean albumin and bilirubin values significantly improved between baseline and follow-up week 12. DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in “difficult to treat” HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results.

Published
2019

126. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

Author

Marcellusi, A, Viti, R, Kondili, L, Rosato, S, Vella, S, Mennini, F, Quaranta, M, Tosti, M, Weimer, L, Ferrigno, L, D'Angelo, F, Falzano, L, Benedetti, A, Schiada, L, Cucco, M, Giacometti, A, Brescini, L, Castelletti, S, Drenaggi, D, Mazzaro, C, Angarano, G, Milella, M, Dileo, A, Rendina, M, Contaldo, A, Iannone, A, La Fortezza, F, Rizzi, M, Cologni, G, Bolondi, L, Benevento, F, Serio, I, Andreone, P, Caraceni, P, Guarneri, V, Margotti, M, Simonetti, G, Mazzella, G, Verucchi, G, Donati, V, Mian, P, Rimenti, G, Rossini, A, Contessi, G, Castelli, F, Zaltron, S, Spinetti, A, Odolini, S, Leandro, G, Cozzolongo, R, Zappimbulso, M, Russello, M, Benigno, R, Coco, C, Torti, C, Costa, C, Greco, G, Mazzitelli, M, Pisani, V, Cosco, L, Quintieri, F, Desiena, M, Giancotti, F, Vecchiet, J, Falasca, K, Mastroianni, A, Apuzzo, G, Chidichimo, L, Foschi, F, Dall'Aglio, A, Libanore, M, Segala, D, Sighinolfi, L, Bartolozzi, D, Salomoni, E, Blanc, P, Baragli, F, Delpin, B, Mariabelli, E, Mazzotta, F, Poggi, A, Zignego, A, Monti, M, Madia, F, Xheka, A, Cela, E, Santantonio, T, Bruno, S, Viscoli, C, Alessandrini, A, Curti, C, Dibiagio, A, Nicolini, L, Balletto, E, Mastroianni, C, Blerta, K, Prati, D, Raffaele, L, Andreoletti, M, Perboni, G, Costa, P, Manzini, L, Raimondo, G, Filomia, R, Lazzarin, A, Morsica, G, Salpietro, S, Puoti, M, Baiguera, C, Vassalli, S, Rumi, M, Labanca, S, Zuin, M, Giorgini, A, Orellana, D, D'Arminiomonforte, A, Debona, A, Solaro, S, Fargion, S, Valenti, L, Periti, G, Pelusi, S, Galli, M, Calvi, E, Milazzo, L, Peri, A, Lampertico, P, Borghi, M, D'Ambrosio, R, Degasperi, E, Vinci, M, Villa, E, Bernabucci, V, Bristot, L, Pereira, F, Chessa, L, Pasetto, M, Loi, M, Gori, A, Beretta, I, Pastore, V, Soria, A, Strazzabosco, M, Ciaccio, A, Gemma, M, Borgia, G, Foggia, A, Zappulo, E, Gentile, I, Buonomo, A, Abrescia, N, Maddaloni, A, Caporaso, N, Morisco, F, Camera, S, Donnarumma, L, Coppola, C, Amoruso, D, Staiano, L, Saturnino, M, Coppola, N, Martini, S, Monari, C, Federico, A, Dallio, M, Loguercio, C, Gaeta, G, Brancaccio, G, Nardone, G, Sgamato, C, D'Adamo, G, Alberti, A, Gonzo, M, Piovesan, S, Chemello, L, Buggio, A, Cavalletto, L, Barbaro, F, Castelli, E, Floreani, A, Cazzagon, N, Franceschet, I, Russo, F, Zanetto, A, Franceschet, E, Madonia, S, Cannizzaro, M, Montalto, G, Licata, A, Capitano, A, Craxi, A, Petta, S, Calvaruso, V, Rini, F, Ferrari, C, Negri, E, Orlandini, A, Pesci, M, Bruno, R, Lombardi, A, Zuccaro, V, Gulminetti, R, Asti, A, Villaraggia, M, Mondelli, M, Ludovisi, S, Baldelli, F, Di Candilo, F, Parruti, G, Di Stefano, P, Sozio, F, Gizzi, M, Brunetto, M, Colombatto, P, Coco, B, Surace, L, Foti, G, Pellicano, S, Fornaciari, G, Schianchi, S, Vignoli, P, Massari, M, Corsini, R, Garlassi, E, Ballardini, G, Andreoni, M, Cerva, C, Angelico, M, Gasbarrini, A, Siciliano, M, De Siena, M, Nosotti, L, Taliani, G, Biliotti, E, Santori, M, Spaziante, M, Tamburini, F, Vullo, V, D'Ettorre, G, Cavallari, E, Gebremeskel, T, Pavone, P, Cauda, R, Cingolani, A, Lamonica, S, D'Offizi, G, Lionetti, R, Visco Comandini, U, Grieco, A, D'Aversa, F, Picardi, A, De Vincentis, A, Galati, G, Gallo, P, Dell'Unto, C, Aghemo, A, Gatti Comini, A, Persico, M, Masarone, M, Anselmo, M, De Leo, P, Marturano, M, Brunelli, E, Ridolfi, F, Schimizzi, A, Ayoubi Khajekini, M, Framarin, L, Di Perri, G, Cariti, G, Boglione, L, Cardellino, C, Marinaro, L, Saracco, G, Ciancio, A, Toniutto, P, Alterini, G, Capra, F, Ieluzzi, D, Marcellusi A., Viti R., Kondili L. A., Rosato S., Vella S., Mennini F. S., Quaranta M. G., Tosti M. E., Weimer L. E., Ferrigno L., D'Angelo F., Falzano L., Benedetti A., Schiada L., Cucco M., Giacometti A., Brescini L., Castelletti S., Drenaggi D., Mazzaro C., Angarano G., Milella M., DiLeo A., Rendina M., Contaldo A., Iannone A., La Fortezza F., Rizzi M., Cologni G., Bolondi L., Benevento F., Serio I., Andreone P., Caraceni P., Guarneri V., Margotti M., Simonetti G., Mazzella G., Verucchi G., Donati V., Mian P., Rimenti G., Rossini A., Contessi G. B., Castelli F., Zaltron S., Spinetti A., Odolini S., Leandro G., Cozzolongo R., Zappimbulso M., Russello M., Benigno R., Coco C., Torti C., Costa C., Greco G., Mazzitelli M., Pisani V., Cosco L., Quintieri F., DeSiena M., Giancotti F., Vecchiet J., Falasca K., Mastroianni A., Apuzzo G., Chidichimo L., Foschi F. G., Dall'Aglio A. C., Libanore M., Segala D., Sighinolfi L., Bartolozzi D., Salomoni E., Blanc P., Baragli F., DelPin B., Mariabelli E., Mazzotta F., Poggi A., Zignego A. L., Monti M., Madia F., Xheka A., Cela E. M., Santantonio T. A., Bruno S. R., Viscoli C., Alessandrini A. I., Curti C., DiBiagio A., Nicolini L. A., Balletto E., Mastroianni C., Blerta K., Prati D., Raffaele L., Andreoletti M., Perboni G., Costa P., Manzini L., Raimondo G., Filomia R., Lazzarin A., Morsica G., Salpietro S., Puoti M., Baiguera C., Vassalli S., Rumi M. G., Labanca S., Zuin M., Giorgini A., Orellana D., D'ArminioMonforte A., Debona A., Solaro S., Fargion S., Valenti L., Periti G., Pelusi S., Galli M., Calvi E., Milazzo L., Peri A., Lampertico P., Borghi M., D'Ambrosio R., Degasperi E., Vinci M., Villa E., Bernabucci V., Bristot L., Pereira F., Chessa L., Pasetto M. C., Loi M., Gori A., Beretta I., Pastore V., Soria A., Strazzabosco M., Ciaccio A., Gemma M., Borgia G., Foggia A., Zappulo E., Gentile I., Buonomo A. R., Abrescia N., Maddaloni A., Caporaso N., Morisco F., Camera S., Donnarumma L., Coppola C., Amoruso D. C., Staiano L., Saturnino M. R., Coppola N., Martini S., Monari C., Federico A., Dallio M., Loguercio C., Gaeta G. B., Brancaccio G., Nardone G., Sgamato C., D'Adamo G., Alberti A., Gonzo M., Piovesan S., Chemello L., Buggio A., Cavalletto L., Barbaro F., Castelli E., Floreani A., Cazzagon N., Franceschet I., Russo F. P., Zanetto A., Franceschet E., Madonia S., Cannizzaro M., Montalto G., Licata A., Capitano A. R., Craxi A., Petta S., Calvaruso V., Rini F., Ferrari C., Negri E., Orlandini A., Pesci M., Bruno R., Lombardi A., Zuccaro V., Gulminetti R., Asti A., Villaraggia M., Mondelli M., Ludovisi S., Baldelli F., Di Candilo F., Parruti G., Di Stefano P., Sozio F., Gizzi M. C., Brunetto M. R., Colombatto P., Coco B., Surace L., Foti G., Pellicano S., Fornaciari G., Schianchi S., Vignoli P., Massari M., Corsini R., Garlassi E., Ballardini G., Andreoni M., Cerva C., Angelico M., Gasbarrini A., Siciliano M., De Siena M., Nosotti L., Taliani G., Biliotti E., Santori M., Spaziante M., Tamburini F., Vullo V., D'Ettorre G., Cavallari E. N., Gebremeskel T. S., Pavone P., Cauda R., Cingolani A., Lamonica S., D'Offizi G., Lionetti R., Visco Comandini U., Grieco A., D'Aversa F., Picardi A., De Vincentis A., Galati G., Gallo P., Dell'Unto C., Aghemo A., Gatti Comini A., Persico M., Masarone M., Anselmo M., De Leo P., Marturano M., Brunelli E., Ridolfi F., Schimizzi A. M., Ayoubi Khajekini M., Framarin L., Di Perri G., Cariti G., Boglione L., Cardellino C., Marinaro L., Saracco G. M., Ciancio A., Toniutto P., Alterini G., Capra F., Ieluzzi D., Marcellusi, A, Viti, R, Kondili, L, Rosato, S, Vella, S, Mennini, F, Quaranta, M, Tosti, M, Weimer, L, Ferrigno, L, D'Angelo, F, Falzano, L, Benedetti, A, Schiada, L, Cucco, M, Giacometti, A, Brescini, L, Castelletti, S, Drenaggi, D, Mazzaro, C, Angarano, G, Milella, M, Dileo, A, Rendina, M, Contaldo, A, Iannone, A, La Fortezza, F, Rizzi, M, Cologni, G, Bolondi, L, Benevento, F, Serio, I, Andreone, P, Caraceni, P, Guarneri, V, Margotti, M, Simonetti, G, Mazzella, G, Verucchi, G, Donati, V, Mian, P, Rimenti, G, Rossini, A, Contessi, G, Castelli, F, Zaltron, S, Spinetti, A, Odolini, S, Leandro, G, Cozzolongo, R, Zappimbulso, M, Russello, M, Benigno, R, Coco, C, Torti, C, Costa, C, Greco, G, Mazzitelli, M, Pisani, V, Cosco, L, Quintieri, F, Desiena, M, Giancotti, F, Vecchiet, J, Falasca, K, Mastroianni, A, Apuzzo, G, Chidichimo, L, Foschi, F, Dall'Aglio, A, Libanore, M, Segala, D, Sighinolfi, L, Bartolozzi, D, Salomoni, E, Blanc, P, Baragli, F, Delpin, B, Mariabelli, E, Mazzotta, F, Poggi, A, Zignego, A, Monti, M, Madia, F, Xheka, A, Cela, E, Santantonio, T, Bruno, S, Viscoli, C, Alessandrini, A, Curti, C, Dibiagio, A, Nicolini, L, Balletto, E, Mastroianni, C, Blerta, K, Prati, D, Raffaele, L, Andreoletti, M, Perboni, G, Costa, P, Manzini, L, Raimondo, G, Filomia, R, Lazzarin, A, Morsica, G, Salpietro, S, Puoti, M, Baiguera, C, Vassalli, S, Rumi, M, Labanca, S, Zuin, M, Giorgini, A, Orellana, D, D'Arminiomonforte, A, Debona, A, Solaro, S, Fargion, S, Valenti, L, Periti, G, Pelusi, S, Galli, M, Calvi, E, Milazzo, L, Peri, A, Lampertico, P, Borghi, M, D'Ambrosio, R, Degasperi, E, Vinci, M, Villa, E, Bernabucci, V, Bristot, L, Pereira, F, Chessa, L, Pasetto, M, Loi, M, Gori, A, Beretta, I, Pastore, V, Soria, A, Strazzabosco, M, Ciaccio, A, Gemma, M, Borgia, G, Foggia, A, Zappulo, E, Gentile, I, Buonomo, A, Abrescia, N, Maddaloni, A, Caporaso, N, Morisco, F, Camera, S, Donnarumma, L, Coppola, C, Amoruso, D, Staiano, L, Saturnino, M, Coppola, N, Martini, S, Monari, C, Federico, A, Dallio, M, Loguercio, C, Gaeta, G, Brancaccio, G, Nardone, G, Sgamato, C, D'Adamo, G, Alberti, A, Gonzo, M, Piovesan, S, Chemello, L, Buggio, A, Cavalletto, L, Barbaro, F, Castelli, E, Floreani, A, Cazzagon, N, Franceschet, I, Russo, F, Zanetto, A, Franceschet, E, Madonia, S, Cannizzaro, M, Montalto, G, Licata, A, Capitano, A, Craxi, A, Petta, S, Calvaruso, V, Rini, F, Ferrari, C, Negri, E, Orlandini, A, Pesci, M, Bruno, R, Lombardi, A, Zuccaro, V, Gulminetti, R, Asti, A, Villaraggia, M, Mondelli, M, Ludovisi, S, Baldelli, F, Di Candilo, F, Parruti, G, Di Stefano, P, Sozio, F, Gizzi, M, Brunetto, M, Colombatto, P, Coco, B, Surace, L, Foti, G, Pellicano, S, Fornaciari, G, Schianchi, S, Vignoli, P, Massari, M, Corsini, R, Garlassi, E, Ballardini, G, Andreoni, M, Cerva, C, Angelico, M, Gasbarrini, A, Siciliano, M, De Siena, M, Nosotti, L, Taliani, G, Biliotti, E, Santori, M, Spaziante, M, Tamburini, F, Vullo, V, D'Ettorre, G, Cavallari, E, Gebremeskel, T, Pavone, P, Cauda, R, Cingolani, A, Lamonica, S, D'Offizi, G, Lionetti, R, Visco Comandini, U, Grieco, A, D'Aversa, F, Picardi, A, De Vincentis, A, Galati, G, Gallo, P, Dell'Unto, C, Aghemo, A, Gatti Comini, A, Persico, M, Masarone, M, Anselmo, M, De Leo, P, Marturano, M, Brunelli, E, Ridolfi, F, Schimizzi, A, Ayoubi Khajekini, M, Framarin, L, Di Perri, G, Cariti, G, Boglione, L, Cardellino, C, Marinaro, L, Saracco, G, Ciancio, A, Toniutto, P, Alterini, G, Capra, F, Ieluzzi, D, Marcellusi A., Viti R., Kondili L. A., Rosato S., Vella S., Mennini F. S., Quaranta M. G., Tosti M. E., Weimer L. E., Ferrigno L., D'Angelo F., Falzano L., Benedetti A., Schiada L., Cucco M., Giacometti A., Brescini L., Castelletti S., Drenaggi D., Mazzaro C., Angarano G., Milella M., DiLeo A., Rendina M., Contaldo A., Iannone A., La Fortezza F., Rizzi M., Cologni G., Bolondi L., Benevento F., Serio I., Andreone P., Caraceni P., Guarneri V., Margotti M., Simonetti G., Mazzella G., Verucchi G., Donati V., Mian P., Rimenti G., Rossini A., Contessi G. B., Castelli F., Zaltron S., Spinetti A., Odolini S., Leandro G., Cozzolongo R., Zappimbulso M., Russello M., Benigno R., Coco C., Torti C., Costa C., Greco G., Mazzitelli M., Pisani V., Cosco L., Quintieri F., DeSiena M., Giancotti F., Vecchiet J., Falasca K., Mastroianni A., Apuzzo G., Chidichimo L., Foschi F. G., Dall'Aglio A. C., Libanore M., Segala D., Sighinolfi L., Bartolozzi D., Salomoni E., Blanc P., Baragli F., DelPin B., Mariabelli E., Mazzotta F., Poggi A., Zignego A. L., Monti M., Madia F., Xheka A., Cela E. M., Santantonio T. A., Bruno S. R., Viscoli C., Alessandrini A. I., Curti C., DiBiagio A., Nicolini L. A., Balletto E., Mastroianni C., Blerta K., Prati D., Raffaele L., Andreoletti M., Perboni G., Costa P., Manzini L., Raimondo G., Filomia R., Lazzarin A., Morsica G., Salpietro S., Puoti M., Baiguera C., Vassalli S., Rumi M. G., Labanca S., Zuin M., Giorgini A., Orellana D., D'ArminioMonforte A., Debona A., Solaro S., Fargion S., Valenti L., Periti G., Pelusi S., Galli M., Calvi E., Milazzo L., Peri A., Lampertico P., Borghi M., D'Ambrosio R., Degasperi E., Vinci M., Villa E., Bernabucci V., Bristot L., Pereira F., Chessa L., Pasetto M. C., Loi M., Gori A., Beretta I., Pastore V., Soria A., Strazzabosco M., Ciaccio A., Gemma M., Borgia G., Foggia A., Zappulo E., Gentile I., Buonomo A. R., Abrescia N., Maddaloni A., Caporaso N., Morisco F., Camera S., Donnarumma L., Coppola C., Amoruso D. C., Staiano L., Saturnino M. R., Coppola N., Martini S., Monari C., Federico A., Dallio M., Loguercio C., Gaeta G. B., Brancaccio G., Nardone G., Sgamato C., D'Adamo G., Alberti A., Gonzo M., Piovesan S., Chemello L., Buggio A., Cavalletto L., Barbaro F., Castelli E., Floreani A., Cazzagon N., Franceschet I., Russo F. P., Zanetto A., Franceschet E., Madonia S., Cannizzaro M., Montalto G., Licata A., Capitano A. R., Craxi A., Petta S., Calvaruso V., Rini F., Ferrari C., Negri E., Orlandini A., Pesci M., Bruno R., Lombardi A., Zuccaro V., Gulminetti R., Asti A., Villaraggia M., Mondelli M., Ludovisi S., Baldelli F., Di Candilo F., Parruti G., Di Stefano P., Sozio F., Gizzi M. C., Brunetto M. R., Colombatto P., Coco B., Surace L., Foti G., Pellicano S., Fornaciari G., Schianchi S., Vignoli P., Massari M., Corsini R., Garlassi E., Ballardini G., Andreoni M., Cerva C., Angelico M., Gasbarrini A., Siciliano M., De Siena M., Nosotti L., Taliani G., Biliotti E., Santori M., Spaziante M., Tamburini F., Vullo V., D'Ettorre G., Cavallari E. N., Gebremeskel T. S., Pavone P., Cauda R., Cingolani A., Lamonica S., D'Offizi G., Lionetti R., Visco Comandini U., Grieco A., D'Aversa F., Picardi A., De Vincentis A., Galati G., Gallo P., Dell'Unto C., Aghemo A., Gatti Comini A., Persico M., Masarone M., Anselmo M., De Leo P., Marturano M., Brunelli E., Ridolfi F., Schimizzi A. M., Ayoubi Khajekini M., Framarin L., Di Perri G., Cariti G., Boglione L., Cardellino C., Marinaro L., Saracco G. M., Ciancio A., Toniutto P., Alterini G., Capra F., and Ieluzzi D.

Abstract

Objective: We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy. Methods: A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulative costs saved to recover the Italian NHS investment in DAA treatment. Three different PITER enrolment periods, which covered the full DAA access evolution in Italy, were considered. Results: The disease stages of 2657 patients who consecutively underwent DAA therapy from January 2015 to December 2017 at 30 PITER clinical centres were standardized for 1000 patients. The investment in DAAs was considered to equal €25 million, €15 million, and €9 million in 2015, 2016, and 2017, respectively. For patients treated in 2015, the BPT was not achieved, because of the disease severity of the treated patients and high DAA prices. For 2016 and 2017, the estimated BPTs were 6.6 and 6.2 years, respectively. The total cost savings after 20 years were €50.13 and €55.50 million for 1000 patients treated in 2016 and 2017, respectively. Conclusions: This study may be a useful tool for public decision makers to understand how HCV clinical and epidemiological profiles influence the economic burden of HCV.

Published
2019

127. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel

Author

Di Marco, Vito, Capra, Marcello, Angelucci, Emanuele, Borgna-Pignatti, Caterina, Telfer, Paul, Harmatz, Paul, Kattamis, Antonis, Prossamariti, Luciano, Filosa, Aldo, Rund, Deborah, Gamberini, Maria Rita, Cianciulli, Paolo, De Montalembert, Marianne, Gagliardotto, Francesco, Foster, Graham, Grangè, Jean Didier, Cassarà, Filippo, Iacono, Angela, Cappellini, Maria Domenica, Brittenham, Gary M., Prati, Daniele, Pietrangelo, Antonello, Craxì, Antonio, and Maggio, Aurelio

Published
2010
Full Text
View/download PDF

128. Beneficence and equity: how the covid-19 pandemic exposed our weaknesses in Italy

Author

Craxi Lucia, Vergano Marco, Craxi Lucia, and Vergano Marco

Subjects
Settore MED/02 - Storia Della Medicina, COVID 19, Allocation, Bioethics, Public Health, Italy, Settore MED/41 - Anestesiologia
Abstract

How did Italy face the issue of allocating beds in Intensive Care Units and ventilators during the COVID-19 outbreak? At the beginning of the epidemic, the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care issued recommendations that sparked a heated debate. Later, the National Bioethics Committee, the ethical advisory board of the Government, has issued a document, which recognizes that the only admissible criterion to employ in a "pandemic emergency triage" is a clinical criterion. The document actually doesn’t address some core ethical issues, leaving many unanswered questions.

Published
2020

129. LA REAL CASA DEI MATTI DI PALERMO E IL MITO LETTERARIO DEL BARONE PISANI

Author

Lucia Craxi and Lucia Craxi

Subjects
Madness, Pisani, Real Casa dei Matti, Palermo
Abstract

This story is about a government, which considered the management of madness not a medical issue but a matter of law and order, and a 64 years old official who became the director of a madhouse having no medical nor managing expertise in mental disease, but just humanity and dedication. But most of all its the story of their attempt to project an image of themselves and of what they had done, that turned out in something completely different: a literary myth which went so far to reach the pen of Alexandre Dumas and Edgar Allan Poe.

Published
2020

130. The wounded self-portrait as an expression of the experiential dimension of disease

Author

Antonio Gioacchino Spagnolo, Simona Giardina, Lucia Craxi, and Antonio Gioacchino Spagnolo, Simona Giardina, Lucia Craxi

Subjects
Settore MED/02 - Storia Della Medicina, Self-portrait, wounded body, Van Gogh, Kahlo, Bacon, Klee, Munch
Abstract

The present article aims at giving an ethical-anthropological interpretation of the body wounded by the disease, under the perspective of the wounded self-portrait, a genre selected by some artists who, between the nineteenth and the twentieth century, pictured their physical or psychological malaise (Van Gogh, Kahlo, Munch, Bacon, Klee). Getting acquainted with artistic language, particularly when it arises from personal experience, has an educational value for healthcare professional, as it helps to catch “the history from below”, as Roy Porter called it, which is the history from the patient’s perspective. Dans cet article les auteurs donnent une interprétation anthropologique au corps humain blessé par la maladie, illustrée par un autoportrait défiguré par la blessure, genre choisi par un nombre d’artistes qui au XIXième et XXième siècle peignaient leur malaise physique ou mental (Van Gogh, Kahlo, Munch, Bacon, Klee). Une meilleure compréhension du language artistique, en particulier quand celui-ci émane d’une experience personelle, représente une valeur éducative pour le professionnel des soins de santé, puisqu’elle aide à saisir ‘l’histoire par l’intérieur’, comme le disait Roy Porter, c’est-à-dire l’histoire du point de vue personnel du patient.

Published
2020

134. Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C

Author

Di Maio, Velia Chiara, Barbaliscia, Silvia, Fabeni, Lavinia, Teti, Elisabetta, Paolucci, Stefania, Minichini, Carmine, Aragri, Marianna, La Rosa, Katia Yu, Pasquazzi, Caterina, Milana, Martina, Foroghi, Luca, Pollicino, Teresa, Licata, Anna, Pieri, Alessandro, Palitti, Valeria Pace, Bruzzone, Bianca, Valeria Micheli, Bertoli, Ada, Baiocchi, Leonardo, Callegaro, Maria Paola, Carioti, Luca, Pellicelli, Adriano, Morisco, Filomena, Gulminetti, Roberto, Novati, Stefano, Lichtner, Miriam, Mastroianni, Claudio M., Di Lorenzo, Francesco, Andreone, Pietro, Rossetti, Barbara, Marenco, Simona, Taliani, Gloria, Boeri, Enzo, Hasson, Hamid, Monno, Laura, Nicolini, Laura Ambra, Landonio, Simona, Paternoster, Claudio, Puoti, Massimo, Babudieri, Sergio, Quartini, Mariano, Iapadre, Nerio, Cozzolongo, Raffaele, Sangiovanni, Vincenzo, Parruti, Giustino, Sarmati, Loredana, Coppola, Nicola, Zazzi, Maurizio, Raimondo, Giovanni, Mario, Angelico, Perno, Carlo-Federico, Andreoni, Massimo, Craxi, Antonio, and Silberstein, Francesca Ceccherini

Subjects
Hepatology
Published
2020

135. SIRT5 rs12216101 T > G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD

Author

Federico Salomone, Rosaria Maria Pipitone, Francesco Malvestiti, Paola Dongiovanni, Miriam Longo, Angela Maria Amorini, Alfio Distefano, Giovanni Li Volti, Giuseppe Lazzarino, Ester Ciociola, Grazia Pennisi, Rossana Porcasi, Daniela Cabibi, Antonio Craxi, Anna Ludovica Fracanzani, Luca Valenti, Salvatore Petta, and Stefania Grimaudo

Subjects
Hepatology
Published
2022

137. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

Author

Zeuzem, S., Flisiak, R., Vierling, J. M., Mazur, W., Mazzella, G., Thongsawat, S., Abdurakhmanov, D., Van Kính, N., Calistru, P., Heo, J., Stanciu, C., Gould, M., Makara, M., Hsu, S.-J., Buggisch, P., Samuel, D., Mutimer, D., Nault, B., Merz, M., Bao, W., Griffel, L. H., Brass, C., Naoumov, N. V., Tanno, Hugo, Bessone, Fernando, Terg, Ruben, Frider, Bernardo, Bertuzzi, Romina, Desmond, Paul, Zekry, Amany, Weltman, Martin, George, Jacob, Crawford, Darrell, Matthews, Gail, Moreno, Christophe, Van Vlierberghe, Hans, Reynaert, Hendrik, Gould, Michael, Lee, Samuel, Ramji, Alnoor, Tam, Edward, Marotta, Paul, Yoshida, Eric, Wong, Florence, Feld, Jordan, Samuel, Didier, Marcellin, Patrick, Alric, Laurent, Zarski, Jean-Pierre, Zoulim, Fabien, Buggisch, Peter, Hinrichsen, Holger, Goeser, Tobias, Zeuzem, Stefan, Galle, Peter, Berg, Thomas, Schott, Eckart, Rasenack, Jens, Gerken, Guido, Wedemeyer, Hans, Tsang, Owen, Yuen, Man-Fung, Chan, Henry, Hui, Aric Josun, Makara, Mihaly, Tornai, Istvan, Gervain, Judit, Szalay, Ferenc, Varga, Marta, Horvath, Gabor, Hunyady, Bela, Vincze, Aron, Mazzella, Giuseppe, Gaeta, Giovanni Battista, Alberti, Alfredo, Colombo, Massimo, Andreone, Pietro, Rizzetto, Mario, Angelico, Mario, Craxi, Antonio, Picciotto, Antonino, Sacchi, Paolo, Vinci, Maria, Invernizzi, Pietro, Bruno, Savino, Heo, Jeong, Lee, Younjae, Cho, Mong, Han, Sangyoung, Lee, Jinwoo, Ahn, Sanghoon, Lim, Youngsuk, Hwang, Seonggyu, Sanchez, Juan, Muñoz, Linda, Maldonado, Hector, Mazur, Wlodzimierz, Flisiak, Robert, Jablkowski, Maciej, Kryczka, Wieslaw, Halota, Waldemar, Calistru, Petre, Prelipcean, Cristina, Musa, Manuela, Stanciu, Carol, Manuc, Mircea, Tanasescu, Coman, Dumitrascu, Dan, Abdurakhmanov, Djamal, Chulanov, Vladimir, Nikitin, Igor, Zhdanov, Konstantin, Esaulenko, Elena, Maevskaya, Marina, Znoyko, Olga, Lamoglia, Ricard Sola, Ferret, Maria Buti, Garcia-Samaniego, Javier, Gomez, Manuel Romero, Diago, Moises, Calleja, Jose Luis, Hsu, Shih-Jer, Chuang, Wan-Long, Hu, Tsung-Hui, Peng, Cheng-Yuan, Chen, Chi-Yi, Kao, Jia-Horng, Thongsawat, Satawat, Sukeepaisarnjaroen, Wattana, Piratvisuth, Teerha, Tanwandee, Tawesak, Komolmit, Piyawat, Agarwal, Kosh, Mutimer, David, Brown, Ashley, Foster, Graham, McPherson, Stuart, Ryder, Stephen, Poulos, John, Rustgi, Vinod, Lyche, Kip, Omarro, Steven, Vierling, John, Ghalib, Reem, Karnam, Umaprasanna, Peine, Craig, Galati, Joseph, Person, John, De La Torre, Andrew, Ravendhran, Natarajan, Mushahwar, Andria, OʼLeary, Jacqueline, Lee, William, Lawitz, Eric, Ankoma-Sey, Victor, King, John, Pound, David, Scarsella, Anthony, Thuluvath, Paul, Pockros, Paul, Mailliard, Mark, Shiffman, Mitchell, Sylvestre, Diana, Heiman, David, Jacobson, Ira, Bacon, Bruce, Dimitroff, James, Reindollar, Robert, Tobias, Hillel, Godofsky, Eliot, Rodriguez-Torres, Maribel, Bennett, Michael, Ben-Zvi, Jeffrey, Van, Kinh Nguyen, Dao, Long, Huu, Hoang Bui, Minh, Yen Lam, Le Thanh, Ly, and Van Long, Dao

Published
2015
Full Text
View/download PDF

139. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Author

Dongiovanni, Paola, Petta, Salvatore, Maglio, Cristina, Fracanzani, Anna Ludovica, Pipitone, Rosaria, Mozzi, Enrico, Motta, Benedetta Maria, Kaminska, Dorota, Rametta, Raffaela, Grimaudo, Stefania, Pelusi, Serena, Montalcini, Tiziana, Alisi, Anna, Maggioni, Marco, Kärjä, Vesa, Borén, Jan, Käkelä, Pirjo, Di Marco, Vito, Xing, Chao, Nobili, Valerio, Dallapiccola, Bruno, Craxi, Antonio, Pihlajamäki, Jussi, Fargion, Silvia, Sjöström, Lars, Carlsson, Lena M., Romeo, Stefano, and Valenti, Luca

Published
2015
Full Text
View/download PDF

140. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Author

Poynard, Thierry, Colombo, Massimo, Bruix, Jordi, Schiff, Eugene, Terg, Ruben, Flamm, Steven, Moreno-Otero, Ricardo, Carrilho, Flair, Schmidt, Warren, Berg, Thomas, McGarrity, Thomas, Heathcote, E. Jenny, Gonçales, Fernando, Diago, Moises, Craxi, Antonio, Silva, Marcelo, Bedossa, Pierre, Mukhopadhyay, Pabak, Griffel, Louis, Burroughs, Margaret, Brass, Clifford, and Albrecht, Janice

Published
2009
Full Text
View/download PDF

142. Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study

Author

Riveiro-Barciela, Mar, primary, Marcos-Fosch, Cristina, additional, Martinez-Valle, Fernando, additional, Bronte, Fabrizio, additional, Orozco, Olimpia, additional, Sanz-Pérez, Isidro, additional, Torres, Daniele, additional, Salcedo, Maria-Teresa, additional, Petta, Salvatore, additional, Esteban, Rafael, additional, Craxi, Antonio, additional, and Buti, Maria, additional

Published
2021
Full Text
View/download PDF

143. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

Author

Sasso, Ferdinando Carlo, primary, Pafundi, Pia Clara, additional, Caturano, Alfredo, additional, Galiero, Raffaele, additional, Vetrano, Erica, additional, Nevola, Riccardo, additional, Petta, Salvatore, additional, Fracanzani, Anna Ludovica, additional, Coppola, Carmine, additional, Di Marco, Vito, additional, Solano, Antonio, additional, Lombardi, Rosa, additional, Giordano, Mauro, additional, Craxi, Antonio, additional, Perrella, Alessandro, additional, Sardu, Celestino, additional, Marfella, Raffaele, additional, Salvatore, Teresa, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2021
Full Text
View/download PDF

145. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Schiff, E. Schinazi, R. Sebastiani, G. Seguin-Devaux, C. Shanmugam, R.P. Sharara, A. Shilton, S. Shouval, D. Sievert, W. Simonova, M. Sohrabpour, A.A. Sonderup, M. Soza, A. Wendy Spearman, C. Steinfurth, N. Sulkowski, M. Tan, S.-S. Tanaka, J. Tashi, D. Thein, H.-H. Thompson, P. Tolmane, I. Toy, M. Valantinas, J. Van de Vijver, D. Vélez-Möller, P. Vince, A. Waked, I. Wang, S. Wedemeyer, H. Wong, V. Xie, Q. Yamada, S. Yang, H.-I. Yesmembetov, K. Yilmaz, Y. Younossi, Z. Yu, M.-L. Yuen, M.-F. Yurdaydin, C. Yusuf, A. Zekry, A. Zeuzem, S. Polaris Observatory Collaborators

Subjects
digestive system diseases
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

146. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

Author

Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., Zeuzem S., Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., and Zeuzem S.

Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries' progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to <=5 per 100 000, reduce HBV prevalence among 1-year-olds to <=0.1%, reduce HBV and HCV mortality to <=5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.Copyright © 2020 John Wiley & Sons Ltd

Published
2021

147. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, Homie, Blach, Sarah, Razavi-Shearer, Devin, Abaalkhail, Faisal, Abbas, Zaigham, Abdallah, Ayat, Abrao Ferreira, Paulo, Abu Raddad, Laith Jamal, Adda, Danjuma, Agarwal, Kosh, Aghemo, Alessio, Ahmed, Aijaz, Al-Busafi, Said A., Al-hamoudi, Waleed, Al-Kaabi, Saad, Al-Romaihi, Hamad, Aljarallah, Badr, AlNaamani, Khalid, Alqahtani, Saleh, Alswat, Khalid, Altraif, Ibrahim, Asselah, Tarik, Bacon, Bruce, Bessone, Fernando, Bizri, Abdul Rahman, Block, Tim, Bonino, Ferruccio, Brandão-Mello, Carlos Eduardo, Brown, Kimberly, Bruggmann, Philip, Brunetto, Maurizia Rossana, Buti, Maria, Cabezas, Joaquín, Calleja, Jose Luis, Castro Batänjer, Erika, Chan, Henry Lik Yuen, Chang, Henry, Chen, Chien Jen, Christensen, Peer Brehm, Chuang, Wan Long, Cisneros, Laura, Cohen, Chari, Colombo, Massimo, Conway, Brian, Cooper, Curtis, Craxi, Antonio, Croes, Esther, Popping, Stephanie, Toy, Mehlika, Van de Vijver, David, Razavi, Homie, Blach, Sarah, Razavi-Shearer, Devin, Abaalkhail, Faisal, Abbas, Zaigham, Abdallah, Ayat, Abrao Ferreira, Paulo, Abu Raddad, Laith Jamal, Adda, Danjuma, Agarwal, Kosh, Aghemo, Alessio, Ahmed, Aijaz, Al-Busafi, Said A., Al-hamoudi, Waleed, Al-Kaabi, Saad, Al-Romaihi, Hamad, Aljarallah, Badr, AlNaamani, Khalid, Alqahtani, Saleh, Alswat, Khalid, Altraif, Ibrahim, Asselah, Tarik, Bacon, Bruce, Bessone, Fernando, Bizri, Abdul Rahman, Block, Tim, Bonino, Ferruccio, Brandão-Mello, Carlos Eduardo, Brown, Kimberly, Bruggmann, Philip, Brunetto, Maurizia Rossana, Buti, Maria, Cabezas, Joaquín, Calleja, Jose Luis, Castro Batänjer, Erika, Chan, Henry Lik Yuen, Chang, Henry, Chen, Chien Jen, Christensen, Peer Brehm, Chuang, Wan Long, Cisneros, Laura, Cohen, Chari, Colombo, Massimo, Conway, Brian, Cooper, Curtis, Craxi, Antonio, Croes, Esther, Popping, Stephanie, Toy, Mehlika, and Van de Vijver, David

Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.

Published
2021

148. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

Author

Fonds de Recherche du Québec, McGill University, Petta, Salvatore, Sebastiani, Giada, Viganò, Mauro, Ampuero, Javier, Wai-Sun Wong, Vincent, Boursier, Jerome, Berzigotti, Annalisa, Bugianesi, Elisabetta, Fracanzani, Anna Ludovica, Cammà, Calogero, Enea, Marco, des Grottes, Marraud, Di Marco, Vito, Younes, Ramy, Keyrouz, Aline, Mazzola, Sergio, Mendoza, Yuly, Pennisi, Grazia, Romero-Gómez, Manuel, Craxi, Antonio, de Ledinghen, Victor, Fonds de Recherche du Québec, McGill University, Petta, Salvatore, Sebastiani, Giada, Viganò, Mauro, Ampuero, Javier, Wai-Sun Wong, Vincent, Boursier, Jerome, Berzigotti, Annalisa, Bugianesi, Elisabetta, Fracanzani, Anna Ludovica, Cammà, Calogero, Enea, Marco, des Grottes, Marraud, Di Marco, Vito, Younes, Ramy, Keyrouz, Aline, Mazzola, Sergio, Mendoza, Yuly, Pennisi, Grazia, Romero-Gómez, Manuel, Craxi, Antonio, and de Ledinghen, Victor

Abstract

[Background & Aims] Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events., [Methods] We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3–F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19–63 months)., [Results] Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02–1.04; P < .001), HCC (HR, 1.03; 95% CI, 1.00–1.04; P = .003), and liver-related death (HR, 1.02; 95% CI, 1.02–1.03; P = .005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05–2.51; P = .04), HCC (HR, 1.72; 95% CI, 1.01–3.02; P = .04), overall mortality (HR, 1.73; 95% CI, 1.11–2.69; P = .01), and liver-related mortality (HR, 1.96; 95% CI, 1.10–3.38; P = .02)., [Conclusions] In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

Published
2021

149. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

Author

Sydney Medical Foundation, University of Sydney, National Health and Medical Research Council (Australia), Australian Government, European Commission, Bayoumi, Ali, Elsayed, Asmaa, Han, Shuanglin, Petta, Salvatore, Adams, Leon A., Aller, Rocío, Khan, Anis, García-Monzón, Carmelo, Arias-Loste, María Teresa, Miele, Luca, Latchoumanin, Olivier, Alenizi, Shafi, Gallego-Durán, Rocío, Fischer, Janett, Berg, Thomas, Craxi, Antonio, Metwally, Mayada, Qiao, Liang, Liddle, Christopher, Yki-Järvinen, Hannele, Bugianesi, Elisabetta, Romero-Gómez, Manuel, George, Jacob, Eslam, Mohammed, Sydney Medical Foundation, University of Sydney, National Health and Medical Research Council (Australia), Australian Government, European Commission, Bayoumi, Ali, Elsayed, Asmaa, Han, Shuanglin, Petta, Salvatore, Adams, Leon A., Aller, Rocío, Khan, Anis, García-Monzón, Carmelo, Arias-Loste, María Teresa, Miele, Luca, Latchoumanin, Olivier, Alenizi, Shafi, Gallego-Durán, Rocío, Fischer, Janett, Berg, Thomas, Craxi, Antonio, Metwally, Mayada, Qiao, Liang, Liddle, Christopher, Yki-Järvinen, Hannele, Bugianesi, Elisabetta, Romero-Gómez, Manuel, George, Jacob, and Eslam, Mohammed

Abstract

Fibroblast growth factor 21 (FGF21) is a liver-derived hormone with pleiotropic beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in metabolic diseases. Interventions that restore metabolic homeostasis reduce FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral tissues is the initiating factor in altering FGF21 levels and function in humans is unknown. A genetic approach is used to help resolve this paradox. The authors demonstrate that the primary event in dysmetabolic phenotypes is the elevation of FGF21 secretion. The latter is regulated by translational reprogramming in a genotype- and context-dependent manner. To relate the findings to tissues outcomes, the minor (A) allele of rs838133 is shown to be associated with increased hepatic inflammation in patients with metabolic associated fatty liver disease. The results here highlight a dominant role for translation of the FGF21 protein to explain variations in blood levels that is at least partially inherited. These results provide a framework for translational reprogramming of FGF21 to treat metabolic diseases.

Published
2021

150. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

Author

Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L. A., Aller, R., Khan, A., Garcia-Monzon, C., Arias-Loste, M. T., Miele, Luca, Latchoumanin, O., Alenizi, S., Gallego-Duran, R., Fischer, J., Berg, T., Craxi, A., Metwally, M., Qiao, L., Liddle, C., Yki-Jarvinen, H., Bugianesi, E., Romero-Gomez, M., George, J., Eslam, M., Miele L. (ORCID:0000-0003-3464-0068), Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L. A., Aller, R., Khan, A., Garcia-Monzon, C., Arias-Loste, M. T., Miele, Luca, Latchoumanin, O., Alenizi, S., Gallego-Duran, R., Fischer, J., Berg, T., Craxi, A., Metwally, M., Qiao, L., Liddle, C., Yki-Jarvinen, H., Bugianesi, E., Romero-Gomez, M., George, J., Eslam, M., and Miele L. (ORCID:0000-0003-3464-0068)

Abstract

Fibroblast growth factor 21 (FGF21) is a liver-derived hormone with pleiotropic beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in metabolic diseases. Interventions that restore metabolic homeostasis reduce FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral tissues is the initiating factor in altering FGF21 levels and function in humans is unknown. A genetic approach is used to help resolve this paradox. The authors demonstrate that the primary event in dysmetabolic phenotypes is the elevation of FGF21 secretion. The latter is regulated by translational reprogramming in a genotype- and context-dependent manner. To relate the findings to tissues outcomes, the minor (A) allele of rs838133 is shown to be associated with increased hepatic inflammation in patients with metabolic associated fatty liver disease. The results here highlight a dominant role for translation of the FGF21 protein to explain variations in blood levels that is at least partially inherited. These results provide a framework for translational reprogramming of FGF21 to treat metabolic diseases.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results